Figure 1.

Decoy-CTCF Repress Tumor Proliferation and Migration In Vitro

(A) The TCGA database of overall tumor demonstrated prolonged survival time in patients with low CTCF expression. (B) Schematic diagram of decoy-CTCF. Top panel: the wild-type CTCF with zinc-finger (ZF) domain, N-terminal (NT), and C-terminal (CT) domain. Middle panel: dsCTCF with ZF domain and Sss1 domain. Bottom panel: deCTCF with ZF domain and EGFP domain. (C) Fluorescence microscope showed the deCTCF expressed in both tumor and normal transfected cells. (D and E) qPCR showed the deCTCF (D) and dsCTCF (E) expressed in both tumor and normal transfected cells. (F) Western blot verified that the dsCTCF expressed in both tumor and normal transfected cells. (G) CCK8 assay demonstrated that dsCTCF could significantly reduce the proliferation of transfected ocular melanoma but have no effect on normal cells. (H) Plate clone formation assay verified that dsCTCF or deCTCF could significantly reduce the proliferation of transfected ocular melanoma. (I) Transwell migration assay showed that dsCTCF or deCTCF could significantly reduce the migration ability of ocular melanoma. (J) Scratch test suggested that dsCTCF or deCTCF could significantly reduce the migration ability.